Icon plc Aktie
Icon plc Aktie
Was spricht für und gegen Icon plc in den nächsten Jahren?
Pro
Kontra
Rendite von Icon plc im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Icon plc | -2,67 % | -1,63 % | 11,19 % | -20,85 % | -23,60 % | -14,21 % | - |
| Alkermes plc | -2,42 % | -3,97 % | -9,02 % | -15,38 % | -13,57 % | 3,02 % | 35,20 % |
| Ironwood Pharmaceuticals | -1,96 % | 2,74 % | 10,29 % | -9,09 % | -28,57 % | -73,55 % | -70,00 % |
| Novocure Ltd | -2,16 % | 6,51 % | 13,42 % | -65,32 % | -62,07 % | -84,26 % | -91,44 % |
Kommentare
News
3 Healthcare Pathbreakers With Long-Term Tailwinds
In the world of healthcare stocks, a major innovation, new medical device, or successful drug treatment can cement a firm's position as a leader. Unfortunately, many firms chase after these goals
LVM Capital Management Dumps 16,000 ICON Public Shares Worth $2.6 million
According to an SEC filing dated July 2, 2025, LVM Capital Management reduced its position in ICON Public Limited (NASDAQ:ICLR) by selling 16,096 shares. The transaction was valued at $2.58 million
ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainability
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2025 with a number of business awards, recognising the





